U.S. orders another 100 million doses of the BioNTech/Pfizer COVID-19 vaccine


BioNTech SE’s
stock was down 0.3% and shares of Pfizer Inc.
were up 0.1% in premarket trading on Friday after the companies said the U.S. now plans to purchase an additional 100 million doses of its COVID-19 vaccine for $1.95 billion. This brings the total number of vaccine doses supplied in the U.S. by BioNTech and Pfizer to 300 million. Their vaccine requires two doses, meaning that the vaccine can be administered to 150 million people. The news follows Moderna Inc.’s
announcement on Thursday that the U.S. had also ordered an additional 100 million doses of its two-dose, mRNA-based vaccine. Over the past 12 months, BioNTech’s stock rallied 299.3%, shares of Pfizer are down 3.7%, and the broader S&P 500
is up 16.6%.


- Advertisement -

Leave A Reply

Your email address will not be published.